Many cancer patients are diagnosed at a stage in which the cancer is too far advanced to be cured, and most cancer treatments are effective in only a minority of patients undergoing therapy. Thus, there is tremendous opportunity to improve the outcome for people with cancer by enhancing detection and treatment approaches. Biomarkers will be instrumental in making that transition. Advances in biotechnology and genomics have given scientists new hope that biomarkers can be used to improve cancer screening and detection, to improve the drug development process, and to enhance the effectiveness and safety of cancer care by allowing physicians to tailor treatment for individual patients—an approach known as personalized medicine. However, progress overall has been slow, despite considerable effort and investment, and there are still many challenges and obstacles to overcome before this paradigm shift in oncology can become a reality.
Committee on Developing Biomarker-Based Tools for Cancer Screening, Diagnosis, and Treatment, Sharyl J. Nass and Harold L. Moses, Editors
1 Front Matter; 2 Summary; 3 1 Introduction; 4 2 Methods, Tools, and Resources Needed to Discover and Develop Biomarkers; 5 3 Guidelines, Standards, Oversight, and Incentives Needed for Biomarker Development; 6 4 Methods and Process Needed for Clinical Adoption and Evaluation of Biomarker-Based Diagnostics; 7 Acronyms and Glossary; 8 Appendix: Developing Biomarker-Based Tools for Cancer Screening, Diagnosis,and Treatment: The State of the Science, Evaluation, Implementation, and Economics, Workshop Summary--Margie Patlak and Sharyl Nass, Rapporteurs
National Research Council, Division of Behavioral and Social Sciences and Education, Institute of Medicine, and Families Board on Children, Youth, Steve Olson
Institute of Medicine, Board on the Health of Select Populations, and Transgender Health Issues and Research Gaps and Opportunities Committee on Lesbian, Gay, Bisexual
Institute of Medicine, Board on Population Health and Public Health Practice, Division of Health Promotion and Disease Prevention, Division of International Health
Institute of Medicine, Committee to Develop Methods Useful to the Department of Veteran Affairs in Estimating Its Physician Requirements, Joseph Lipscomb
Institute of Medicine, Board on Health Care Services, Committee on Cancer Clinical Trials and the NCI Cooperative Group Program, John Mendelsohn, Harold L. Moses, Sharyl J. Nass
and Medicine National Academies of Sciences, Engineering, Institute of Medicine, Board on Health Care Services, Committee on Policy Issues in the Clinical Development and Use of Biomarkers for Molecularly Targeted Therapies, Harold L. Moses, Jonathan K. Phillips, Laurene A. Graig
and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Health Care Services, National Cancer Policy Forum, Sharyl J. Nass, Margie Patlak, Emily Zevon, Erin Balogh
and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Health Care Services, National Cancer Policy Forum, Sharyl J. Nass, Erin Balogh
and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Health Care Services, and Independence Forum on Aging, Disability, Forum on Mental Health and Substance Use Disorders, Sharyl J. Nass, Kat M. Anderson, Alexandra Andrada
and Medicine National Academies of Sciences, Engineering, Health and Medicine Division, Board on Health Sciences Policy, Board on Health Care Services, Forum on Mental Health and Substance Use Disorders, Joe Alper, Sharyl J. Nass, Alexandra Andrada